February 21, 2018 6:40 PM ET

Pharmaceuticals

Company Overview of Par Pharmaceutical, Inc.

Company Overview

Par Pharmaceutical, Inc. develops, manufactures, and distributes generic drugs in the United States. The company was incorporated in 2003 and is based in Spring Valley, New York. Par Pharmaceutical, Inc. operates as a subsidiary of Endo International plc.

One Ram Ridge Road

Spring Valley, NY 10977

United States

Founded in 2003

Phone:

201-802-4000

Fax:

201-391-5364

Key Executives for Par Pharmaceutical, Inc.

President
Age: 55
Other Professional
Age: 62
Compensation as of Fiscal Year 2017.

Par Pharmaceutical, Inc. Key Developments

Par Pharmaceutical Inc. Launched the 5 and 40 Mg Strengths of its Generic Focalin XR Capsules in the US

Intellipharmaceutics International Inc. announced that its U.S. marketing partner, Par Pharmaceutical Inc., has launched the 5 and 40 mg strengths of its generic Focalin XR (dexmethylphenidate hydrochloride extended-release) capsules in the U.S. The launch of the 5 and 40 mg strengths complements the 10, 15, 20, 25, 30 and 35 mg strengths of generic Focalin XR previously launched and marketed by Par. Under a licensing and commercialization agreement between the Company and Par, the company receives quarterly profit-share payments on Par's U.S. sales of generic Focalin XR. Focalin XR, a drug used in the treatment of attention deficit hyperactivity disorder, is marketed by Novartis Pharmaceuticals Corporation.

Par Pharmaceutical Launches 25 and 35 Mg Strengths of its Generic Focalin XR

Intellipharmaceutics International Inc.  announced that its United States marketing partner, Par Pharmaceutical, has launched the 25 and 35 mg strengths of its generic Focalin XR®  (dexmethylphenidate hydrochloride extended-release) capsules in the U.S.  The U.S. Food and Drug Administration ("FDA") has granted final approval to Par’s abbreviated new drug application (“ANDA”) for its generic Focalin XR® capsules in the 5, 10, 15, 20, 25, 30, 35 and 40 mg strengths. The Company is unable to state or estimate an actual launch date of any remaining strengths, but currently intends to provide an update once it is advised by Par of the launch of any additional strengths of its generic Focalin XR®.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
NYC2012, Inc. United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Par Pharmaceutical, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.